GSK attacks ‘meritless claims’ over heartburn drug Zantac

INSUBCONTINENT EXCLUSIVE:

GSK and its consumer spin-off brand Haleon have hit back at market speculation over heartburn drug Zantac that sent its shares plummeting

on Thursday.